Tuesday, August 30, 2022
Acorda Therapeutics, Inc., has announced a license agreement with Asieris Pharmaceuticals, a biotechnology company based in China, for its preclinical asset Nepicastat. As per the agreement, Acorda will receive an upfront payment of $500,000, and additional payments of up to $7 million upon achieving regulatory milestones. Acorda will also be entitled to royalties on future net sales.
Nepicastat is a small molecule drug, and the license agreement covers its development for all non-psychiatric indications and therapeutic uses. Acorda's U.S. subsidiary, Biotie Therapies, Inc., has held the asset.
